They showed that cancer patients with POLE/POLD1 mutations showed significantly longer overall survival in comparison to the wild-type population (34 vs. 18 months, p = 0.04), and that in addition to cancer type and MSI status, POLE/POLD1 mutations were an independent risk factor for identification of patients who would benefit from ICI treatment. This evidence concerns the gene POLD1 and cancer.